(Q40263422)

19 September 2017

title

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice (English)

1 reference

Sathyamangalam Swaminathan

19 September 2017

0 references

object named as

Sathyamangalam Swaminathan

series ordinal

3

0 references

Navin Khanna

series ordinal

4

object named as

Navin Khanna

1 reference

19 September 2017

Upasana Arora

1

1 reference

19 September 2017

Poornima Tyagi

series ordinal

2

1 reference

19 September 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

19 September 2017

1 reference

19 September 2017

volume

31

1 reference

19 September 2017

issue

6

1 reference

19 September 2017

page(s)

873-878

1 reference

Dengue vaccines: state of the art.

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Domain III of the envelope protein as a dengue vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Virus-like particles: flexible platforms for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

HBV core particles as a carrier for B cell/T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Heterologous protein production using the Pichia pastoris expression system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Measurement of protein using bicinchoninic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

M2e-based universal influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.016

10.1016/J.VACCINE.2012.12.016

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference